Hospira Files IPR Petitions on Genentech’s Trastuzumab-related Patents

Goodwin
Contact

On Friday, Hospira filed the following petitions – IPR2017-00731 (U.S. Patent No. 7,846,441), and IPR2017-00737 and IPR2017-00739 (both for U.S. Patent No. 7,892,549).  According to these petitions, the patents are drawn to methods of using trastuzumab in combination with certain other agents for the treatment of cancers.  Trastuzumab is the active agent in Herceptin®.

We have added these petitions to our IPR Tracker Page, where we post selected important filings in IPRs related to biologics.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising.

© Goodwin

Written by:

Goodwin
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide